For informational purposes only — not investment advice

← Back to signals

MDLN

SHORTINSIDER SELL

MEDLINE INC

Research: Finviz ↗·Perplexity ↗

🗄 Viewing archived Q2 2026 data — frozen, no longer refreshed.

Funds
4
Score
3.70
vs SPY
-0.0%
Stock return (since Q-end)
-0.7%
SPY return (since Q-end)
-0.7%
Current price
$39.17
Days to cover (short int.)
5.1d↑+45.1%
as of 2026-09-30 · shares short vs 2026-06-30

News Summary

Neutral

Medline delivered strong Q3 earnings with 10% revenue growth and 12% EBITDA growth, beating expectations and raising full-year organic sales guidance for the third consecutive quarter, supported by analyst upgrades and a $1B share repurchase. However, significant headwinds persist: an FDA warning letter for manufacturing violations in June 2026, resulting remediation costs that reduced Q2 earnings, a major product line exit (Front Line Care) in October, and ongoing securities fraud investigations by multiple law firms.

Red flags

  • •FDA warning letter (June 2026) for significant Current Good Manufacturing Practice violations in finished pharmaceuticals
  • •Q2 net income down 58.3% year-over-year; remediation of FDA issues acknowledged as causing 'earnings loss'
  • •Exited Front Line Care product category (October 2026) with inventory impairment and disposal costs
  • •Multiple securities fraud investigations underway by Bleichmar Fonti & Auld, Pomerantz, and others regarding manufacturing and product quality disclosures
  • •Board director resignation and transition disclosed in late October 2026

Funds Reducing / Exiting (4)

FundManagerShares Held∆ SharesPosition Value% of FundQoQStatus
Viking GlobalAndreas Halvorsen4.8M-6,592,741$191M1.4%-58%Existing
Durable Capital PartnersHenry Ellenbogen2.6M-4,638,500$104M3.3%-64%Existing
Maverick CapitalLee Ainslie0−796K—0.4%-100%EXITED
Point72Steve Cohen0−3.3M—0.3%-100%EXITED

Shares Held reflects quarter-end positions for partial reductions. Funds that fully exited show 0 shares held. ∆ Shares is the change from the prior quarter. % of Fund is the prior-quarter position size — how much of the book was sold down.

Signal History

QuarterDirectionFundsScorevs SPY
Q3 2026LONG34.71+15.2%
Q2 2026SHORT43.70-0.0%
Q1 2026LONG44.85-39.4%

Same issuer appearing in consecutive quarters — persistent institutional conviction. Returns are frozen at each archived quarter's last refresh.

Insider Activity

NameTitleTypeSharesPriceValueFiledSrc
GIC Private Ltd—SELL7.8M$35.15$274.77M2026-10-08↗
GIC Private Ltd—SELL2.1M$35.05$73.22M2026-10-06↗
GIC Private Ltd—SELL7.2M$35.05$251.76M2026-10-06↗
GIC Private Ltd—SELL1.7M$35.78$60.42M2026-10-05↗
GIC Private Ltd—SELL7.1M$34.33$245.35M2026-10-02↗
GIC Private Ltd—SELL2.6M$35.35$90.88M2026-10-02↗
GIC Private Ltd—SELL100K$35.80$3.58M2026-08-14↗
GIC Private Ltd—SELL1.5M$35.80$53.70M2026-08-13↗
GIC Private Ltd—SELL590K$35.58$21.00M2026-08-07↗
GIC Private Ltd—SELL272K$35.33$9.61M2026-08-06↗
GIC Private Ltd—SELL1.7M$35.46$60.67M2026-08-05↗
GIC Private Ltd—SELL266K$36.48$9.69M2026-08-05↗

Beneficial Ownership (13D/13G)

FilerFormShares% of ClassFiledSrc
Capital Research Global InvestorsSC 13G47.8M5.4%2026-11-13↗
GIC Private LimitedSC 13G/A74.6M8.5%2026-11-06↗
GIC Private LimitedSC 13G/A114.4M13.0%2026-10-30↗
Hellman & Friedman Capital Partners X (Parallel), L.P.SC 13G/A61.1M6.4%2026-08-11↗
BX Mozart ML-2 Holdco L.P.SC 13G/A89.5M10.2%2026-08-07↗
FMR LLCSC 13G46.9M5.5%2026-08-06↗
Carlyle Group Inc.SC 13G/A187.1M20.6%2026-05-15↗
Abu Dhabi Investment AuthoritySC 13G/A41.4M4.9%2026-05-07↗
Hellman & Friedman Capital Partners X (Parallel), L.P.SC 13G/A74.5M7.9%2026-05-06↗
BX Mozart ML-2 Holdco L.P.SC 13G/A109.3M12.9%2026-05-01↗

SC 13D = active intent to influence control (10-day filing deadline after crossing 5%). SC 13G = passive accumulation, no intent to influence control.